A5003073002- Systemic Lupus Erythematosus Research
- Systemic Sclerosis and Related Diseases
- Monoclonal and Polyclonal Antibodies Research
- Atherosclerosis and Cardiovascular Diseases
- Salivary Gland Disorders and Functions
- Lymphoma Diagnosis and Treatment
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Chronic Lymphocytic Leukemia Research
- Rheumatoid Arthritis Research and Therapies
- Biosimilars and Bioanalytical Methods
- Health Systems, Economic Evaluations, Quality of Life
- Immunodeficiency and Autoimmune Disorders
- SARS-CoV-2 and COVID-19 Research
- Autoimmune Bullous Skin Diseases
- Adrenal Hormones and Disorders
- Celiac Disease Research and Management
- Pharmaceutical Economics and Policy
- Case Reports on Hematomas
- Connective tissue disorders research
- Musculoskeletal synovial abnormalities and treatments
- Cutaneous lymphoproliferative disorders research
- Vaccine Coverage and Hesitancy
- Musculoskeletal Disorders and Rehabilitation
- Spondyloarthritis Studies and Treatments
- Paraquat toxicity studies and treatments
University of Manchester
2018-2024
Manchester Academic Health Science Centre
2022-2024
Manchester University NHS Foundation Trust
2022-2024
NIHR Oxford Musculoskeletal Biomedical Research Centre
2023-2024
Versus Arthritis
2018-2024
Manchester Royal Infirmary
2024
Centre for Epidemiology Versus Arthritis
2021-2023
Royal Lancaster Infirmary
2022
Centre for Inflammation Research
2018
University of Brighton
2016
The primary aim of the CHANGE survey is to determine current state gender equity within rheumatology, and secondarily, review physician perspective on bullying, harassment equipoise opportunities rheumatology. e-survey a cross-sectional self-reported questionnaire adapted from EULAR's in academic rheumatology task force. was launched January 2023; it available six languages distributed widely via organizations social media. Eligible participants include rheumatologist physicians health-care...
Abstract Background The pandemic presented unique challenges for individuals with autoimmune and rheumatic diseases (AIRDs) due to their underlying condition, the effects of immunosuppressive treatments, increased vaccine hesitancy. Objectives COVID‐19 vaccination in (COVAD) study, a series ongoing, patient self‐reported surveys were conceived vision being tool gather perspectives on AIRDs. It involved multinational, multicenter collaborative effort amidst global lockdown. Methods Leveraging...
To quantify how well phase III randomised clinical trials in both SLE and lupus nephritis (LN) represents a real-world cohort. Literature reviews were performed of major published (n=12) LN (n=6) (ClinicalTrials.gov). Inclusion exclusion criteria common across these collated for non-renal or trials, applied to patients recruited the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR) starting either biological standard-of-care (SOC) therapies. We 837 BILAG-BR from September...
Abstract Objectives Poor health-related quality of life (HRQoL) is well recognized in patients with CTD. We hypothesized that subgroups across the spectrum CTD experience different HRQoL patterns and aimed to determine patient-level characteristics associated these subgroups. Methods Using eight continuous domains Medical Outcomes Study 36-item Short Form (SF-36) questionnaire we performed data-driven clustering derive latent profiles (LPs) distinct patterns. Multivariable ordinal logistic...
<h3>Objective</h3> This study aimed to identify protein biomarkers associated with patient-reported symptom burden and health-related quality of life (HR-QoL) in patients a systemic autoimmune rheumatic disease (SARD), positive for anti-SSA. <h3>Methods</h3> Anti-SSA SARD were recruited prospectively. Baseline 6-months HR-QoL determined by patient VAS (0–100), ESSPRI (0–10). Proximity extension immunoassays (OIink) used measure normalised expression (NPX) sera across 88 inflammatory...
<h3>Objectives</h3> To explore the variations in glucocorticoid prescribing practices according to physician's years of experience managing SLE. <h3>Methods</h3> The LUPHPOS (LUpus PHysician' Perspective On glucocorticoidS) study is an online cross-sectional self-reported survey on perspective glucocorticoids management SLE, disseminated between April-August 2023. We have compared responses practitioners with ≤10 (shorter experience, SE) and those >10 (longer LE). <h3>Results</h3> A...
<h3>Background:</h3> Systemic autoimmune diseases such as Mixed Connective Tissue Disease (MCTD), Sjögren's disease (SjD) and systemic lupus erythematosus (SLE) are clinically heterogeneous. At the molecular level, they share some common features expression of autoantibodies. The presence an IFN stimulated gene (ISG) signature in many patients suggests that pathways drive ISG induction, Toll-like receptor (TLR) 7, may be activated across diseases, targeting these lead to clinical benefit...
Anti-Ro/SS-A antibodies are prevalent across systemic autoimmune rheumatic diseases (SARDs) and may signify a distinctive phenotype. This study aimed to identify protein biomarkers associated with symptom burden health-related quality of life (HR-QoL), use protein-based stratification clinically meaningful clusters inflammatory pathways implicated. Anti-Ro positive SARD patients were enrolled in 6-month pilot study. HR-QoL was determined using patient-reported visual analogue scale, assessed...
Abstract Background/Aims The overlapping clinical and serological features among connective tissue diseases (CTDs) suggest a shared molecular aetiology. A taxonomy of CTDs offers new opportunities in trial design, which can potentially be translated into targeted treatment. In previous study 164 patients, we identified type I interferon (IFN) positive subgroup within an unselected CTD cohort associated with specific features. Here, aim to investigate the relationship between IFN...
<h3>Background:</h3> Glucocorticoids (GCs) play a pivotal role in the treatment of active SLE, however their use is associated with risk organ damage which irreversible. The lack specific guidelines due to insufficient evidence, and inherent heterogeneity disease, pose challenges for GC initiation withdrawal. <h3>Objectives:</h3> To explore variations prescribing practices attitudes toward initiating/withdrawing therapy amongst physicians practicing European non-European countries....
<h3>Background:</h3> Rates of clinical response to medical therapies may be suboptimal in patients with SLE, and furthermore such responses discordant patient reported outcomes. <h3>Objectives:</h3> To compare the proportion active SLE a therapy at 12 months using clinician assessment investigate outcomes between health-related quality life (HR-QoL) moderate-severe UK. <h3>Methods:</h3> Patients disease (1xBILAG A or 2xBILAG B) commencing rituximab (RTX), belimumab standard care medication...
<h3>Purpose</h3> Connective tissue diseases (CTDs) are heterogeneous with overlapping clinical features and shared immunopathology. We sought to assess characteristics, arterial stiffness therapeutic exposures in a mixed CTD cohort using both clinician diagnosis classification criteria. specifically compared these factors undifferentiated (UCTD) systemic lupus erythematosus (SLE). <h3>Method</h3> Data was collected prospectively 181 patients Lupus Extended Autoimmune Phenotype Study (LEAP)...
lymphocyte count.Anti-Ro alone was seen in seven patients with alopecia and none without.Conclusion: Self reported lupus is common, occurring 59.7% of our cohort most commonly as a change texture volume hair over the whole scalp.Alopecia not related to age or ethnicity but appeared associated anti-Ro antibody.Alopecia other cutaneous SLE manifestations rash (62.5%) ulceration (47.5%), suggesting that it disease rather than medication related.Alopecia significant burden anxiety.